Durable Melanoma Therapy Outcomes in Long-Term Data Analysis

Five-year data reveal encouraging melanoma therapy outcomes for patients with high-risk stage III/IV melanoma after complete resection. The combination of intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, with KEYTRUDA (pembrolizumab) reduced the risk of recurrence or death by 49 percent and the risk of distant metastasis or death by 59 percent compared with KEYTRUDA alone at a median follow-up of 60.3 months.

An exploratory analysis indicated an encouraging trend toward improved overall survival with a hazard ratio of 0.471. These results from Moderna and Merck demonstrate sustained clinical benefit and build directly on earlier analyses reported at approximately three years.

Immune Clonotype Growth Drives Deeper Protection

The primary endpoint of recurrence-free survival (RFS) showed a hazard ratio of 0.51, while distant metastasis-free survival (DMFS) recorded a hazard ratio of 0.411, confirming meaningful long-term risk reductions. Subgroup analyses maintained these RFS improvements across age, sex, disease stage, PD-L1 status, BRAF status, tumor mutation burden, and circulating tumor DNA status.

Translational data revealed that intismeran autogene plus KEYTRUDA increased T-cell clonal expansion and generated approximately two-fold higher novel expanded T-cell clonotypes than KEYTRUDA alone. Patients remaining recurrence-free exhibited roughly twice the number of unique novel expanded clonotypes, directly linking these immunological changes to clinical outcomes and supporting the therapy’s proposed mechanism of action.

Patient Selection Rigor in the KEYNOTE-942 Trial

The randomized, open-label Phase 2b trial enrolled 157 patients with high-risk stage III/IV cutaneous melanoma who had undergone complete surgical resection within 13 weeks before the first dose of KEYTRUDA. Patients were assigned in a 2:1 ratio to receive intismeran autogene (1 mg every three weeks for nine doses) plus KEYTRUDA (200 mg every three weeks for up to 18 cycles) or KEYTRUDA alone, with RFS as the primary endpoint, DMFS as a key secondary endpoint, and exploratory assessment of overall survival.

Eligibility required Eastern Cooperative Oncology Group Performance Status of 0 or 1, adequate organ function, and availability of formalin-fixed paraffin-embedded tumor samples suitable for sequencing to identify neoantigens. Intismeran autogene consists of synthetic mRNA encoding up to 34 patient-specific neoantigens designed from the tumor’s unique mutational signature, enabling endogenous translation and antigen presentation to elicit targeted T-cell responses.

Reimbursement Signals from Durable Melanoma Therapy Outcomes

The sustained 49 percent RFS and 59 percent DMFS risk reductions at five years, together with the favorable overall survival trend, provide robust outcomes data that Health Economics and Outcomes Research (HEOR) teams can leverage to quantify long-term clinical value. These melanoma therapy outcomes support potential demonstrations of cost-effectiveness by documenting reduced recurrence and metastasis events that would otherwise drive substantial downstream treatment costs in high-risk melanoma.

The consistent safety profile, with most adverse events attributed to intismeran autogene being Grade 1 or 2 and no potentiation of immune-related adverse events beyond KEYTRUDA alone, further strengthens the benefit-risk profile relevant to reimbursement decision-making. Such tolerability data can inform payer models assessing quality-adjusted survival gains from personalized mRNA therapies.

Moderna and Merck’s nine ongoing Phase 2 and Phase 3 trials across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma indicate a broadening evidence base that could accelerate market access pathways for individualized neoantigen therapies. Fully enrolled Phase 3 studies in adjuvant melanoma and randomized Phase 2 studies in renal cell carcinoma and bladder cancer will generate additional comparative effectiveness evidence critical for pricing and reimbursement negotiations.